CRISPR Therapeutics AG

CRSP

$94.71

+129.82% (1 year change)

Avg closing price

Price range

Market Cap

$6.5 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

$-79.7 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$0.61

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

150.94x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-80.7 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

304

The number of full time employees.

Revenue & Earnings

Balance Sheet

CRISPR Therapeutics AG

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

News

Crispr Therapeutics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis

Crispr Therapeutics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis

Crispr Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily Stock Market Daily, 3 days ago
Stifel Nicolaus Boosts Crispr Therapeutics (NASDAQ:CRSP) Price Target to $93.00

Stifel Nicolaus Boosts Crispr Therapeutics (NASDAQ:CRSP) Price Target to $93.00

Crispr Therapeutics (NASDAQ:CRSP) had its price target hoisted by Stifel Nicolaus from $75.00 to $93.00 in a report released on Wednesday, The Fly reports. Stifel Nicolaus currently has a hold rati...

Zolmax News Zolmax News, 5 days ago
Stifel Nicolaus Increases Crispr Therapeutics (NASDAQ:CRSP) Price Target to $93.00

Stifel Nicolaus Increases Crispr Therapeutics (NASDAQ:CRSP) Price Target to $93.00

Crispr Therapeutics (NASDAQ:CRSP) had its price target lifted by stock analysts at Stifel Nicolaus from $75.00 to $93.00 in a note issued to investors on Wednesday, The Fly reports. The firm presen...

The Olympia Report The Olympia Report, 8 days ago